Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670202 · ClinicalTrials.gov registry record · Phase 2
Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00670202 is a Phase 2 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 2 participants.
The verdict
NCT00670202, a Phase 2 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
To evaluate the causal relationship between Rho/Rho kinase overactivity and mechanisms of vascular dysfunction in patients with atherosclerosis.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Fasudil Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-03-13 |
| Est. Completion | 2011-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670202
The ClinicalTrials.gov registry entry for NCT00670202 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT00670202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00670202 about?
NCT00670202 is a clinical study titled "Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis". To evaluate the causal relationship between Rho/Rho kinase overactivity and mechanisms of vascular dysfunction in patients with atherosclerosis.
What is the current status of trial NCT00670202?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2008-03-13. Estimated completion is 2011-01-20.
What interventions are being tested in trial NCT00670202?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Fasudil Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00670202?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.